Astrazeneca plc

NASDAQ: AZN
$75.03
+$3.83 (+5.4%)
Closing price April 25, 2024
AstraZeneca is a global biopharmaceutical giant, dedicated to the discovery, development, and commercialization of prescription medicines. Its portfolio spans a wide range of areas including cardiovascular, renal, metabolism, oncology, and treatments for rare diseases and COVID-19. The company is known for leading products like Tagrisso, Imfinzi, and Lynparza, among others. AstraZeneca not only serves healthcare professionals and patients worldwide but also engages in significant collaborations, such as with Neurimmune AG, to push the boundaries of medicine. Headquartered in Cambridge, UK, AstraZeneca continues to be at the forefront of addressing global health challenges.

Earnings Previews: AstraZeneca, Bakkt, Hyzon
Here are previews of three earnings reports due for release before markets open on Friday.
Paul Ausick
Published:

Thursday Afternoon Analyst Upgrades and Downgrades: Chipotle, eBay, Nvidia, Qualcomm, Tesla and More
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Thursday, including American Express, Chipotle Mexican Grill, eBay, Nvidia, Qualcomm and Tesla.
Chris Lange
Published:

Earnings Previews: AstraZeneca, Comcast, Merck
Two pharmaceutical companies and a top media firm are on tap to report quarterly results before markets open on Thursday.
Paul Ausick
Published:

Earnings Previews: AbbVie, AstraZeneca, Chevron, Exxon
America's two largest energy companies report March quarter results Friday morning, along with two big pharmaceutical makers.
Paul Ausick
Published:

AstraZeneca, Bumble, McDonald's, Microsoft and More Monday Afternoon Analyst Calls
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including AstraZeneca, Bumble, McDonald’s and Microsoft.
Chris Lange
Published:

Top Analysts Upgrades and Downgrades: Adobe, Altria, AstraZeneca, Crowdstrike, Microsoft, Roblox, Starbucks, Ulta Beauty, Zoom Video and More
Tuesday's top analyst upgrades and downgrades included Adobe, Altria, AstraZeneca, Crowdstrike, Microsoft, Roblox, Starbucks, Ulta Beauty and Zoom Video Communications.
Lee Jackson
Published:
Last Updated:

Top Analyst Upgrades and Downgrades: AstraZeneca, Dollar General, Lowe’s, Nike, Nvidia, Shopify, Square and More
Thursday's top analyst upgrades and downgrades included AstraZeneca, Dollar General, Lowe’s, Nike, Nvidia, Shopify and Square.
Lee Jackson
Published:

Thursday Morning Earnings Watch List: AstraZeneca, Duke, Kraft Heinz, and Pepsi
Here’s a preview of four companies that will be reporting quarterly results before the markets open on Thursday.
Chris Lange
Published:

AstaZeneca, Foot Locker, PayPal, Tesla, Yeti and More of Friday Afternoon's Analyst Calls
Top analyst calls seen Friday afternoon were on AstraZeneca, Foot Locker, PayPal, Tesla, Yeti and more.
Chris Lange
Published:

What This Alexion Acquisition Means for AstraZeneca
Alexion Pharmaceutical shares shot up on Monday after it was announced over the weekend that the company would be acquired by AstraZeneca.
Chris Lange
Published:

Top Analyst Upgrades and Downgrades: Apple, BP, CrowdStrike, Delta, Moody's, NuStar, PPL, Salesforce, Slack, Wells Fargo and More
Monday's top analyst upgrades and downgrades included Apple, BP, CrowdStrike, Delta Air Lines, Moody's, NuStar Energy, PPL, Salesforce.com, Slack Technologies and Wells Fargo.
Jon C. Ogg
Published:

With a Vaccine Coming Soon, Where Do These COVID-19 Stocks Stand?
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Chris Lange
Published:

Top Analyst Upgrades and Downgrades: AIG, CrowdStrike, Datadog, Devon Energy, eGain, Lyft, Moderna, Occidental, Peloton, Yelp and More
Wednesday's top analyst upgrades and downgrades included AIG, CrowdStrike, Datadog, Devon Energy, eGain, Lyft, Moderna, Occidental Petroleum, Peloton Interactive and Yelp.
Jon C. Ogg
Published:

Why the US Is Paying $486 Million to Test AstraZeneca's COVID-19 Drug Cocktail 
Two federal agencies have awarded AstraZeneca some $486 million to develop further the company's treatment and potential vaccine for COVID-19. The payment includes delivery of 100,000 doses of the...
Paul Ausick
Published:

Where We Stand on a Vaccine After Trump Catches COVID-19
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
Chris Lange
Published: